君实生物(01877.HK)特瑞普利单抗新适应症上市申请获批

阿斯达克财经06-26

君实生物(01877.HK) 公布，收到国家药品监督管理局核准签发的《药品注册证书》，公司产品特瑞普利单抗(商品名：拓益)联合注射用紫杉醇用于经充分验证的检测评估PD-L1阳性的复发或转移性三阴性乳腺癌的一线治疗的新适应症上市申请获得批准。这是特瑞普利单抗在内地获批的第十项适应症。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-06-25 16:25。)

AASTOCKS新闻

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2446822291?lang=zh_CN&edition=full","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg","is_english":false,"pubTime":"2024-06-26 01:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2446822291","market":"other","top_or_hot":-1,"title":"君实生物(01877.HK)特瑞普利单抗新适应症上市申请获批","media":"阿斯达克财经","content":"<html><body><div> <span> <p><a href=\"https://laohu8.com/S/688180\">君实生物</a>(01877.HK)<span> </span>公布，收到国家药品监督管理局核准签发的《药品注册证书》，公司产品特瑞普利单抗(商品名：拓益)联合注射用紫杉醇用于经充分验证的检测评估PD-L1阳性的复发或转移性三阴性乳腺癌的一线治疗的新适应症上市申请获得批准。这是特瑞普利单抗在内地获批的第十项适应症。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-06-25 16:25。)<br/><span></span><br/></p><div></div>AASTOCKS新闻 </span> </div></body></html>","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>君实生物(01877.HK)特瑞普利单抗新适应症上市申请获批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n君实生物(01877.HK)特瑞普利单抗新适应症上市申请获批\n</h2>\n\n<h4 class=\"meta\">\n\n<p class=\"head\">\n<strong class=\"h-name small\">阿斯达克财经</strong><span class=\"h-time small\">2024-06-26 01:48</span>\n</p>\n\n</h4>\n\n</header>\n<article>\n<html><body><div> <span> <p><a href=\"https://laohu8.com/S/688180\">君实生物</a>(01877.HK)<span> </span>公布，收到国家药品监督管理局核准签发的《药品注册证书》，公司产品特瑞普利单抗(商品名：拓益)联合注射用紫杉醇用于经充分验证的检测评估PD-L1阳性的复发或转移性三阴性乳腺癌的一线治疗的新适应症上市申请获得批准。这是特瑞普利单抗在内地获批的第十项适应症。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-06-25 16:25。)<br/><span></span><br/></p><div></div>AASTOCKS新闻 </span> </div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1359097/latest-news/AAFN\">阿斯达克财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1359097/latest-news/AAFN","article_id":"2446822291","we_media_id":null,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2446822291","pubTimestamp":1719337680,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"君实生物(01877.HK) 公布，收到国家药品监督管理局核准签发的《药品注册证书》，公司产品特瑞普利单抗(商品名：拓益)联合注射用紫杉醇用于经充分验证的检测评估PD-L1阳性的复发或转移性三阴性乳腺癌的一线治疗的新适应症上市申请获得批准。这是特瑞普利单抗在内地获批的第十项适应症。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-06-25 16:25。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688180":"君实生物","BK0239":"医药制造","BK1515":"抗疫概念","BK1161":"生物科技","01877":"君实生物","BK1583":"高瓴概念"},"translate_title":"Junshi Biotech (01877. HK) Toripalimab New Indication Marketing Application Approved","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688180":1,"01877":1},"content_text":"君实生物(01877.HK) 公布，收到国家药品监督管理局核准签发的《药品注册证书》，公司产品特瑞普利单抗(商品名：拓益)联合注射用紫杉醇用于经充分验证的检测评估PD-L1阳性的复发或转移性三阴性乳腺癌的一线治疗的新适应症上市申请获得批准。这是特瑞普利单抗在内地获批的第十项适应症。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-06-25 16:25。)AASTOCKS新闻","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2446822291"}